SK pharmteco to invest extra $30m for Irish plant expansion, in total $65 million allocated for expansion of SK biotek Ireland’s Dublin-based pharma manufacturing plant.
The Korean Herald: SK pharmteco to invest extra $30m for Irish plant expansion Read More »
SK pharmteco announces $35m investment in Phase 1 of new expansion plan for SK biotek Ireland’s Swords Campus SK pharmteco (SKPT) a global CDMO, part of SK Inc., is pleased to announce $35m investment for the initial phase of an expansion plan for SK biotek Ireland’s Dublin-based pharmaceutical manufacturing plant. This project will provide a
In February’s issue ChemistryToday Brian Mullan Yposkesi’s Head of Development & Innovation has published an article on how C> are a fast growing and promising class of medicines, that offer the possibility of curing conditions with a genetic basis, that have few or no other options for patients. Click here to read Brian’s article: https://www.teknoscienze.com/wp-content/uploads/2022/02/Mullan_CO1_2022.pdf
ChemistryToday C&G Therapy Article by Brian Mullan Head of Development & Innovation Read More »
Link to Original Post: https://www.linkedin.com/posts/sk-group-media_mysk-activity-6889210467521196032-pLZT
#mySK Shelley Vogler Senior Production Planner profiled by SK Group Read More »
A word with…Aslam Malik PhD, CEO SK pharmteco After the acquisition of Yposkesi that allowed SK pharmteco to enter the Cell and Gene Therapy market, are there any other expansion plans you would like to highlight? This is an exciting area for us. Our goal is to become the largest global, end to end
ChimicaOggi|ChemToday Interview with Aslam Malik Read More »
SK Inc. to invest $350M through SK pharmteco. SK Inc. announced on January 9th that it has invested $350 million in the Center for Breakthrough Medicines (CBM), a Pennsylvania-based CGT CDMO, to become the second-largest shareholder…
SK Inc. to invest $350M through SK pharmteco Read More »
Attending CPhI? Pop by Stand 2C46 to meet SK pharmteco’s Pedro Couto Rosado Director of Business Development and Yposkesi’s Dr Brian Mullan Head of Analytical and Process Development, Innovation, Cell and Gene Therapies to hear about #skpharmteco‘s global offering in cell and gene therapy – lentiviral vectors, adeno-associated viral vectors, continuous flow processing, chromatography, SMB, HPAPI, energetic chemistry, controlled substances
Click below to read an article published in the latest issue of tks | publisher, event organiser, media agency written by #SKpharmteco VP Research & Development William DuBay and SK biotek Ireland Limited Director of R&D Samuel Baron focused on ‘Handling HPAPIs for maximum manufacturing flexibility while maintaining adequate safety controls’. https://www.teknoscienze.com/tks_article/handling-hpapis-for-maximum-manufacturing-flexibility-while-maintaining-adequate-safety-controls/
Read a CMO’s perspective on Continuous Process Implementation Recently published in TKS | publisher’s ChemicalToday click the link to read the article by Olivier Dapremont, Executive Director of AMPAC Fine Chemicals an SK pharmteco Company, and view the full supplement https://lnkd.in/efHDCqe
Continuous Process Implementation: A CMO Perspective Read More »
"*" indicates required fields
